Scott Stryker, MD, MPH, DrPH

Amgen, Inc
San Francisco, CA, United States

Director Observational Research
Amgen Inc 2006 to Current

Disclosure information not submitted.

Presentation(s):

• 0306: Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry

  Saturday, November 12, 2022
  1:00 PM – 3:00 PM Eastern Time